{
  "source": "PA-Med-Nec-Repository-Corticotropins.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2028-12\nProgram Prior Authorization/Medical Necessity\nMedication Repository Corticotropins - Acthar Gel® (repository corticotropin\ninjection), Purified Cortrophin Gel™ (repository corticotropin injection\nUSP)\nP&T Approval Date 5/2014, 5/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 10/2021,\n3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nActhar Gel® (repository corticotropin injection) and Purified Cortrophin Gel™ (repository\ncorticotropin injection USP) are adrenocorticotropic hormone (ACTH) analogues medically\nnecessary for:\n• Infantile Spasms: As monotherapy for the treatment of infantile spasms in infants and\nchildren under 2 years of age.\n• Opsoclonus-myoclonus syndrome (i.e., OMS, Kinsbourne Syndrome)\nThe Acthar Gel and Purified Cortrophin Gel package inserts have listed other conditions in\nwhich they may be used without providing supporting clinical evidence. Since Acthar Gel\nand Purified Cortrophin Gel are more costly than alternatives that are at least as likely to\nproduce equivalent therapeutic results, UHCP has determined that use of Acthar Gel and\nPurified Cortrophin Gel is not medically necessary for treatment of the following disorders\nand diseases: multiple sclerosis; rheumatic; collagen; dermatologic; allergic states;\nophthalmic; respiratory; and edematous state.\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Infantile Spasms (i.e., West Syndrome)\n1. Initial Therapy\na. Acthar Gel and Purified Cortrophin Gel will be approved based on both of the\nfollowing criteria\n(1) Diagnosis of infantile spasms (West Syndrome)\n-AND-\n(2) Patient is less than 2 years of age\nAuthorization will be issued for 4 weeks.\n© 2025 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\nAll requests for reauthorization will be denied. All requests for continuation of therapy\nmust be submitted through the appeals process to the UnitedHe",
    "edHealthcare Services, Inc.\n1\n2. Reauthorization\nAll requests for reauthorization will be denied. All requests for continuation of therapy\nmust be submitted through the appeals process to the UnitedHealthcare Pharmacy\nappeals team for consideration.\nB. Opsoclonus-Myoclonus Syndrome (i.e., Kinsbourne Syndrome) (off-label)\n1. Initial Authorization\na. Acthar Gel and Purified Cortrophin Gel will be approved based on the following\ncriteria:\n(1) Diagnosis of opsoclonus-myoclonus syndrome (Kinsbourne Syndrome)\nAuthorization will be issued for 3 months.\n2. Reauthorization\nAll requests for reauthorization will be denied. All requests for continuation of therapy\nmust be submitted through the appeals process to the UnitedHealthcare Pharmacy\nappeals team for consideration.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Acthar Gel [package insert]. Bridgewater, NJ: Mallinckrodt ARD LLC.; February 2024.\n2. Purified Cortrophin Gel [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc.;\nDecember 2024.\n3. Pranzatelli MR, Chun KY, Moxness M, Tate ED, Allison TJ. Cerebrospinal fluid ACTH\nand cortisol in opsoclonus-myoclonus: effect of therapy. Pediatr Neurol. 2005;33(2):121-\n126.\n4. Tate ED, Pranzatelli MR, Verhulst SJ, et al. Active comparator-controlled, rater-blinded\nstudy of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome\n[published correction appears in J Child Neurol. 2012 Oct;27(10):1364. Dosage error in\narticle t",
    "ontrolled, rater-blinded\nstudy of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome\n[published correction appears in J Child Neurol. 2012 Oct;27(10):1364. Dosage error in\narticle text]. J Child Neurol. 2012;27(7):875-884.\n© 2025 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Medical Necessity – Repository Corticotropins -\nActhar Gel (repository corticotropin injection), Purified Cortrophin Gel\n(repository corticotropin injection USP)\nChange Control\n5/2014 New Program\n5/2015 Annual review with no change to clinical coverage.\n9/2016 Annual review. Updated references\n9/2017 Annual review. Updated references.\n9/2018 Annual review. Updated references.\n9/2019 Annual review. Updated references.\n9/2020 Annual review. No changes to coverage criteria. Removed “H.P.” from\nname per package insert.\n10/2021 Annual review. No changes to coverage criteria. Updated references.\n3/2022 Added Purified Cortrophin Gel to program with same coverage criteria\nas Acthar Gel. Updated program name, background and references.\n3/2023 Annual review with no change to coverage criteria. Updated\nreferences.\n3/2024 Annual review with no changes to criteria. Updated references.\n3/2025 Annual review. Removed references to OptumRx throughout criteria\nwithout changes to intent of criteria. Updated background and\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}